CITI/CALL/ILLUMINA/220/0.1/19.06.25 Stock

Warrant

DE000KJ2V7B0

Market Closed - Boerse Frankfurt Warrants 01:26:46 2024-06-19 pm EDT
0.26 EUR 0.00% Intraday chart for CITI/CALL/ILLUMINA/220/0.1/19.06.25
1 month-27.78%
3 months-73.20%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-19 0.26 0.00%
24-06-18 0.26 +4.00%
24-06-17 0.25 -10.71%
24-06-14 0.28 0.00%
24-06-13 0.28 +7.69%

Real-time Boerse Frankfurt Warrants

Last update June 19, 2024 at 01:26 pm EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ILLUMINA, INC.
IssuerLogo Issuer Citi Citi
WKN KJ2V7B
ISINDE000KJ2V7B0
Date issued 2023-12-18
Strike 220 $
Maturity 2025-06-19 (365 Days)
Parity 10 : 1
Emission price 1.35
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.71
Lowest since issue 0.16
Delta0x
Omega 0.000000
Premium0x
Gearing0x
Moneyness 0.4914
Difference Strike 111.9 $
Difference Strike %+50.86%
Intrinsic value 0.000000

Company Profile

Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Sector
-
More about the company

Ratings for Illumina, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Illumina, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
108.1 USD
Average target price
153.6 USD
Spread / Average Target
+42.09%
Consensus